After shedding expensive commercial infrastructure and pivoting to a partnership model, the company is now positioning its ...
The R21/Matrix-M™ malaria vaccine is one step closer to mass rollout, after officially receiving WHO prequalification status, making it eligible for procurement by United Nations agencies. • ...
R21/Matrix-M booster maintains high efficacy against first and multiple episodes of clinical malaria
The phase 1/2b clinical trial on R21/Matrix-M malaria vaccine has recently reported the safety and efficacy of booster vaccination at 12 months. The entire report has been published in The Lancet ...
(RTTNews) - Biopharmaceutical company Novavax, Inc. (NVAX), which advances protein-based vaccines with its novel Matrix-M adjuvant, announced on Monday that it has signed a three-year agreement with ...
(RTTNews) - Novavax, Inc. (NVAX) announced Tuesday progress on its collaboration and license agreement (CLA) with Sanofi SA (SNY) regarding Novavax's Matrix-M adjuvant. The companies have amended ...
GAITHERSBURG, Md., Jan. 20, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) has entered into a license agreement with Pfizer for use of Novavax's Matrix-M® adjuvant. Under the terms of the agreement ...
Novavax Inc. reports fourth-quarter results Thursday before the market opens, as investors look for signs that the vaccine maker’s pivot to a partnership-driven business model is gaining traction. The ...
Novavax has agreed to a deal to let Pfizer use Matrix-M adjuvant in its products for an upfront payment of $30 million and up to another $500 million in milestone payments. The biotech company said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results